Atigotatug
Based on 1 Customer Validation
Atigotatug (BMS-986012) is a fully human IgG1 antibody binds specifically to FucGM1 with an EC50 of 0.15 nmol/L for FucGM1. Atigotatug is a FcγRIIIa ligand with a Kd of 21 nmol/L. Atigotatug demonstrates antitumor efficacy in multiple mouse small cell lung cancer models.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: ≥99.0%
- CAS. Nr.: 2733581-82-1
- Molecular Weight:146.06 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG1 kappa
Human
Fucosyl ganglioside GM1
Atigotatug (serial dilutions) specifically binds purified FucGM1 antigen with an EC50 of 0.15 nmol/L[1].
Atigotatug (serial dilutions) mediates potent ADCC against DMS79 SCLC cells with an EC50 of 0.06 nmol/L[1].
Atigotatug (serial dilutions; 4 hours at 37 °C) mediates CDC against DMS79 SCLC cells with an EC50 of 59 nmol/L following 4 hours of incubation at 37 °C with human complement[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID[1]
-
Dosage:10 mg/kg
-
Administration:three times per week; 3 weeks
-
Result:Induced complete tumor regression in PDX model LU5202 (H-score = 290, high FucGM1 expression).
Achieved 75% TGI 22 days after initial dosing in PDX model LU5170 (H-score = 265, intermediate FucGM1 expression).
Showed no TGI in PDX model LU5249 (H-score = 65, low FucGM1 expression).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 2733581-82-1
-
Appearance Liquid
-
Molecular Weight 146.06 kDa
-
Color Colorless to light yellow
-
SMILES
[Atigotatug]
-
Synonyms
BMS-986012
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Ponath P, et al. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res. 2018 Oct 15;24(20):5178-5189. [Content Brief]
[2]. Paz-Ares LG, et al. TIGOS Trial: A Randomized, Double-Blind, Phase III Trial of Atigotatug and Nivolumab Fixed-Dose Combination With Chemotherapy Versus Atezolizumab With Chemotherapy as First-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. Published online January 26, 2026. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Atigotatug Related Classifications
HY-P990902 Related Classifications
Powered by Bioz
- Atigotatug
- 2733581-82-1
- BMS-986012
- BMS986012
- BMS 986012
- Transmembrane Glycoprotein
- cisplatin
- mouse small cell lung cancer models
- antibody-dependent cellular cytotoxicity
- fucosyl-GM1
- complement-dependent cytotoxicity
- FcγRIIIa
- anti-PD-1
- etoposide
- small cell lung cancer cells
- antibody-dependent cellular phagocytosis
- Inhibitor
- inhibitor
- inhibit